keyword
MENU ▼
Read by QxMD icon Read
search

NSCLC surgery

keyword
https://www.readbyqxmd.com/read/28933452/is-robotic-surgery-for-nsclc-innovative-enough
#1
EDITORIAL
Marcello Migliore
No abstract text is available yet for this article.
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28932579/patient-reported-outcomes-following-video-assisted-thoracoscopic-vats-resection-or-stereotactic-ablative-body-radiotherapy-sabr-for-treatment-of-non-small-cell-lung-cancer-protocol-for-an-observational-pilot-study-lilac
#2
Cecilia Pompili, Kevin N Franks, Alessandro Brunelli, Yusuf S Hussain, Patricia Holch, Matthew E Callister, Jonathan M Robson, Kostas Papagiannopoulos, Galina Velikova
BACKGROUND: Lung cancer is increasingly a disease of the elderly and frail population with a median age of 70 years at diagnosis. Therefore, consideration of the impact of interventions on health-related quality of life (HRQOL) and not only absolute survival is especially important. For non-small cell lung cancer (NSCLC), video-assisted thoracoscopic surgery (VATS) has been gaining popularity over the last few decades, replacing traditional open lobectomies. For high-risk patients who are not deemed suitable for surgery, stereotactic ablative body radiotherapy (SABR) provides a potentially curative alternative...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28932547/does-lung-cancer-surgery-cause-circulating-tumor-cells-a-multicenter-prospective-study
#3
Noriyuki Matsutani, Noriyoshi Sawabata, Masafumi Yamaguchi, Tetsukan Woo, Yujin Kudo, Akikazu Kawase, Satoshi Shiono, Hisae Iinuma, Shigeki Morita, Masafumi Kawamura
BACKGROUND: Cancer relapse is caused by residual isolated tumor cells (ITCs) remaining in the body after surgery. It is speculated that surgical manipulation may cause circulating tumor cells (CTCs) which are the origin of ITCs in the body. The occurrence of CTCs in surgical patients with non-small cell lung cancer (NSCLC) has been shown in retrospective observation, but not prospectively, thus we conducted a multicenter prospective study regarding the occurrence of CTCs by surgical manipulation...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28932546/quantitative-computed-tomography-to-predict-postoperative-fev1-after-lung-cancer-surgery
#4
Alex Fourdrain, Florence De Dominicis, Sophie Lafitte, Jules Iquille, Flavien Prevot, Emmanuel Lorne, Julien Monconduit, Patrick Bagan, Pascal Berna
BACKGROUND: Predicted postoperative FEV1 (ppoFEV1) must be estimated preoperatively prior to surgery for non-small cell lung cancer (NSCLC). We evaluated a lung volumetry approach based on chest computed tomography (CT). METHODS: A prospective study was conducted over a period of one year in eligible lung cancer patients to evaluate the difference between ppoFEV1 and the 3-month postoperative FEV1 (poFEV1). Patients in whom CT was performed in another hospital and those with factors influencing poFEV1, such as atelectasis, pleural effusion, pneumothorax, or pneumonia, were excluded...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28929083/emerging-therapies-for-stage-iii-non-small-cell-lung-cancer-stereotactic-body-radiation-therapy-and-immunotherapy
#5
REVIEW
Sameera S Kumar, Kristin A Higgins, Ronald C McGarry
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. Though initial studies showed a benefit to dose escalation, phase III studies examining dose escalation using standard fractionation or hyperfractionation have failed to show a benefit...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28928848/primary-lymphoepithelioma-like-carcinoma-of-the-lung-an-unusual-cancer-and-clinical-outcomes-of-14-patients
#6
Lan Lin, Tingyan Lin, Bangwei Zeng
Advanced lung cancer is considered to exhibit a poor prognosis; however, the pulmonary lymphoepithelioma-like carcinoma (LELC), a rare subtype of non-small cell lung cancer (NSCLC), exhibits an improved prognosis, compared with non-LELC. The present study aimed at investigating the clinical manifestation, imaging characteristics, pathology, tumor markers, treatment and prognosis of primary LELC of the lung. A total of 14 patients with pulmonary LELC were confirmed by surgery and pathology. Clinical data of those patients were retrospectively reviewed including age, sex, smoking history, symptoms, computed tomography (CT) results, Epstein-Barr virus-encoded RNA (EBER) status, treatment and outcomes...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28922454/surgery-for-t4-lung-cancer-invading-the-thoracic-aorta-do-we-push-the-limits
#7
Giuseppe Marulli, Erino A Rendina, Walter Klepetko, Reinhold Perkmann, Davide Zampieri, Giulio Maurizi, Thomas Klikovits, Francesco Zaraca, Federico Venuta, Egle Perissinotto, Federico Rea
BACKGROUND: Few investigators have described en bloc resection of non-small cell lung cancer (NSCLC) invading the aorta. AIM OF STUDY: Analysis of outcome and prognostic factors for en bloc resections of NSCLC invading the aorta. METHODS: Thirty-five patients (27 males, 8 females; mean age 63 ± 8.6 years) were operated between 1994 and 2015 in four European Centers. HISTOLOGY: 12 (34.3%) squamous cell carcinoma, and 6 (17...
September 18, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28918673/suppression-of-tgf-%C3%AE-1-enhances-chemosensitivity-of-cisplatin-resistant-lung-cancer-cells-through-the-inhibition-of-drug-resistant-proteins
#8
Jin Wang, Yunqing Chen, Fenggang Xiang, Min Li, Hong Li, Jinghua Chi, Keyu Ren
Cisplatin-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but drug resistance occurs in most patients, leading to treatment failure. Recent studies have shown that epithelial-mesenchymal transition (EMT) is associated with drug resistance. However, the underlying mechanism is not entirely clear. In this study, first we showed significant positive correlation between the expression of ERCCl and vimentin, and significant negative correlation between the ERCCl and E-cadherin in the neoadjuvant chemotherapy group and the simple surgery group...
September 18, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28917254/stereotactic-radiotherapy-in-oligometastatic-cancer
#9
Thomas A C Kennedy, Mark T Corkum, Alexander V Louie
Oligometastatic cancer describes a disease state somewhere between localized and metastatic cancer. Proposed definitions of oligometastatic disease have typically used a cut-off of five or fewer sites of disease. Treatment of oligometastatic disease should have the goal of long-term local control, and in selected cases, disease remission. While several retrospective cohorts argue for surgical excision of limited metastases (metastasectomy) as the preferred treatment option for several clinical indications, limited randomized data exists for treating oligometastases...
September 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28906073/salvage-radiotherapy-for-regional-lymph-node-oligo-recurrence-after-radical-surgery-of-non-small-cell-lung-cancer
#10
Ki Ho Seol, Jeong Eun Lee, Joon Yong Cho, Deok Heon Lee, Yangki Seok, Min Kyu Kang
BACKGROUND: Currently, evidence-based guidelines for salvage therapy to treat mediastinal lymph node (LN) oligo-recurrence in post-resection non-small cell lung cancer (NSCLC) are limited. In patients previously treated by surgery without irradiation, radiotherapy (RT) might be safely utilized. We evaluate the clinical outcomes of salvage RT for patients with LN oligo-recurrence that developed after radical surgery for NSCLC. METHODS: Thirty-one patients with stage I-IIIA NSCLC who developed regional LN oligo-recurrence between 2008 and 2013 were reviewed...
September 14, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28886730/annexin-a2-contributes-to-cisplatin-resistance-by-activation-of-jnk-p53-pathway-in-non-small-cell-lung-cancer-cells
#11
Xiaomin Feng, Hao Liu, Zhijie Zhang, Yixue Gu, Huisi Qiu, Zhimin He
BACKGROUND: Development of resistance to therapy continues to be a serious clinical problem in lung cancer management. We previously identified that Annexin A2 is significantly up-regulated in cisplatin-resistant non-small cell lung cancer (NSCLC) A549/DDP cells. However, the exact function and molecular mechanism of Annexin A2 in cisplatin resistance of NSCLCs has not been determined. METHODS: Western blot and qRT-PCR were performed to analyze the protein and mRNA level of indicated molecules, respectively...
September 8, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/28881786/tusc3-induces-autophagy-in-human-non-small-cell-lung-cancer-cells-through-wnt-%C3%AE-catenin-signaling
#12
Yun Peng, Jun Cao, Xiao-Yi Yao, Jian-Xin Wang, Mei-Zuo Zhong, Ping-Ping Gan, Jian-Huang Li
We investigated the effects of tumor suppressor candidate 3 (TUSC3) on autophagy in human non-small cell lung cancer (NSCLC) cells. A total of 118 NSCLC patients (88 males and 30 females) who underwent surgery at our institute were enrolled in the study. Immunohistochemical analysis revealed that TUSC3 protein expression was lower in NSCLC specimens than adjacent normal tissue. Correspondingly, there was greater methylation of TUSC3 in NSCLC than adjacent normal tissue. After transient transfection of A549 NSCLC cells with constructs designed to up-regulate or down-regulate TUSC3 expression, we analyzed the effects of inhibiting the Wnt pathway (XAV939) and autophagy (chloroquine, CQ) on the behavior of NSCLC cells...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28878849/prognostic-value-of-tumor-to-blood-standardized-uptake-ratio-in-patients-with-resectable-non-small-cell-lung-cancer
#13
Seunghyeon Shin, Kyoungjune Pak, In Joo Kim, Bum Soo Kim, Seong Jang Kim
OBJECTIVES: Previously published studies showed that the standard tumor-to-blood standardized uptake value (SUV) ratio (SUR) was a more accurate prognostic method than tumor maximum standardized uptake value (SUVmax). This study evaluated and compared prognostic value of positron emission tomography (PET) parameters and normalized value of PET parameters by blood pool SUV in non-small-cell lung cancer (NSCLC) patients who received curative surgery. METHODS: Seventy-seven patients who underwent curative resection for NSCLC between January 2010 to December 2013 were enrolled in this study...
September 2017: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28865463/carbon-ion-radiotherapy-for-non-small-cell-lung-cancer-with-interstitial-lung-disease-a%C3%A2-retrospective-analysis
#14
Mio Nakajima, Naoyoshi Yamamoto, Kazuhiko Hayashi, Masataka Karube, Daniel K Ebner, Wataru Takahashi, Makoto Anzai, Kenji Tsushima, Yuji Tada, Koichiro Tatsumi, Tadaaiki Miyamoto, Hiroshi Tsuji, Takehiko Fujisawa, Tadashi Kamada
BACKGROUND: Lung cancer is frequently complicated by interstitial lung disease (ILD). Treatment protocols for lung cancer patients with ILD have not been established; surgery, chemotherapy, and radiotherapy can all cause acute exacerbation of ILD. This study evaluated the toxicity and efficacy of carbon ion radiotherapy (CIRT) in patients with non-small cell lung cancer (NSCLC) and ILD. METHODS: Between June 2004 and November 2014, 29 patients diagnosed with NSCLC and ILD were treated with CIRT...
September 2, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28862415/exploring-adjuvant-epidermal-growth-factor-receptor-inhibition-in-non-small-cell-lung-cancer
#15
Giulia M Stella, Davide Piloni
Lung cancer is among the most important causes of death worldwide. Despite the relevant progresses in the personalized approach to lung cancer, patients' survival is still poor. Only a minor fraction of patients can be addressed to surgery for radical tumor removal. Adjuvant chemotherapy is currently recommended for resected stages II and III patients although it is known that it can modestly contribute to survival prolongation. A better identification of molecular markers, predictive of adjuvant chemo response is now mandatory, in order to reduce useless toxicities and identify those patients who could really benefit...
June 2017: Minerva Medica
https://www.readbyqxmd.com/read/28845132/cell-free-dna-in-non-small-cell-lung-cancer
#16
Vaida Gedvilaitė, Diana Schveigert, Saulius Cicėnas
Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC). Advances in the knowledge of the biology of non-small cell lung cancer have revealed molecular information used for systemic cancer therapy targeting metastatic disease, with an important impact on patients' overall survival (OS) and quality of life. However, a biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic...
2017: Acta medica Lituanica
https://www.readbyqxmd.com/read/28844613/percutaneous-thermal-ablation-of-lung-tumors-radiofrequency-microwave-and-cryotherapy-where-are-we-going
#17
J Palussière, V Catena, X Buy
Main indications of percutaneous pulmonary thermal ablation are early stage non-small cell lung carcinoma (NSCLC) for patients who are not amenable to surgery and slow-evolving localized metastatic disease, either spontaneous or following a general treatment. Radiofrequency ablation (RFA) is the most evaluated technique. This technique offers a local control rate ranging between 80 and 90% for tumors <3cm in diameter. Other more recently used ablation techniques such as microwaves and cryotherapy could overcome some limitations of RFA...
September 2017: Diagnostic and Interventional Imaging
https://www.readbyqxmd.com/read/28843357/the-role-of-thoracic-surgery-in-the-therapeutic-management-of-metastatic-non-small-cell-lung-cancer
#18
REVIEW
Elizabeth A David, James M Clark, David T Cooke, Joy Melnikow, Karen Kelly, Robert J Canter
INTRODUCTION: The majority of non-small cell lung cancer (NSCLC) patients are diagnosed with advanced stage disease for whom the prognosis is poor and survival is typically measured in months. Standard therapeutic treatment regimens for patients with stage IV NSCLC typically include chemotherapy and palliative radiation. Despite newer regimens that may include molecularly targeted therapy and immunotherapy, the overall 5-year survival for stage IV disease remains low at 4-6%. Although therapeutic surgery is performed in a minority of cases, accumulating data suggest that thoracic surgery may play several beneficial roles for these patients...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28838382/assessing-the-prognostic-impact-of-the-international-association-for-the-study-of-lung-cancer-proposed-definitions-of-complete-uncertain-and-incomplete-resection-in-non-small-cell-lung-cancer-surgery
#19
Matteo Gagliasso, Giuseppe Migliaretti, Francesco Ardissone
OBJECTIVE: The aim of this study was to assess the prognostic impact of the definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer (NSCLC) surgery, as proposed by the International Association for the Study of Lung Cancer (IASLC). PATIENTS AND METHODS: Single institution retrospective study of consecutive patients undergoing surgery for NSCLC between 1998 and 2007. Complete resection was defined by absence of gross and microscopic residual disease; systematic nodal dissection; no extracapsular extension in distal lymph nodes; and negativity of the highest mediastinal node removed...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28833865/patterns-of-care-for-non-small-cell-lung-cancer-patients-in-belgium-a-population-based-study
#20
L Verleye, C De Gendt, F Vrijens, V Schillemans, C Camberlin, G Silversmit, S Stordeur, E Van Eycken, C Dubois, J Robays, I Wauters, J P Van Meerbeeck
Guidelines recommend surgery for Stage I-II, chemoradiation for Stage III and systemic therapy for Stage IV non-small cell lung cancer (NSCLC). However, patient related factors and patient preferences influence treatment decisions. We investigated patterns of care for Belgian NSCLC patients in 2010-2011, based on population-based data from the Belgian Cancer Registry and administrative databases. The relationship between patient characteristics, institutional diagnostic volume, type of treatment and survival was investigated...
August 18, 2017: European Journal of Cancer Care
keyword
keyword
22646
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"